Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial ResultsBusiness Wire • Thursday
Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026Business Wire • 11/04/26
Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLNBusiness Wire • 10/21/26
Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?Zacks Investment Research • 10/20/26
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG)GlobeNewsWire • 10/20/26
Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On MondayBenzinga • 10/19/26
SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its ShareholdersBusiness Wire • 10/19/26
Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA AssetBusiness Wire • 10/19/26
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, GermanyBusiness Wire • 10/19/26
Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/14/26
Silence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/16/26
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSsBusiness Wire • 08/14/26
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should KnowZacks Investment Research • 08/13/26
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public OfferingBusiness Wire • 08/12/26
Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera TranscriptSeeking Alpha • 08/10/26
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary SharesBusiness Wire • 08/10/26
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class ProfileBusiness Wire • 08/10/26
Silence Therapeutics Reports Second Quarter 2026 Financial and Business ResultsBusiness Wire • 08/10/26